Lyra Therapeutics, Inc. is a clinical-stage biotechnology company developing implantable, office-based therapies for chronic rhinosinusitis (CRS), with LYR-210 as its main product candidate. The company is focused on turning ENT physician office procedures into a commercial treatment pathway, but it currently has no approved product sales and remains dependent on clinical progress and external financing.
−7 679,1 %
−7 266,1 %
−74,1 %
1.71
1.71
| % | |
|---|---|
| LYR-210 | 90% Bioabsorbable implant designed for office-based delivery of therapy for chronic rhinosinusitis. |
| Collaboration and license revenue | 10% Revenue from licensing, development services, and clinical supply under partner agreements. |
| LYR-220 | 0% Second product candidate in development for chronic rhinosinusitis-related use cases. |
Lyra does not sell broadly to consumers; its commercial model depends on ENT physicians, patients with chronic...
They would administer the office-based placement procedure and must adopt the workflow for commercialization to succeed.
Patients with chronic rhinosinusitis are the end users; acceptance depends on tolerability and perceived benefit versus surgery.
They determine whether the office procedure is covered and economically attractive versus endoscopic sinus surgery.
Regional partners such as LianBio fund and commercialize the product in licensed Asian territories.
They support ongoing Phase 3 development and generate the data needed for regulatory review.
Lyra is headquartered in the United States and currently concentrates its development and corporate operations there...
The company’s near-term strategy is to preserve cash, continue the ENLIGHTEN 2 Phase 3 program for LYR-210, and...
The company’s value depends on proving safety and efficacy after the ENLIGHTEN 1 setback.
Lyra expects its current cash runway to extend only into the third quarter of 2026 and needs funding to continue operations.
After the failed primary endpoint in ENLIGHTEN 1, management is exploring transactions that could maximize shareholder value.
If LYR-210 is approved, adoption will require physician workflow change, reimbursement support, and manufacturing scale-up.
Lyra is a high-risk development-stage company with substantial doubt about its ability to continue as a going concern,...
Management disclosed substantial doubt about continuing as a going concern and expects cash to fund operations only into Q3 2026.
LYR-210 failed the primary endpoint in ENLIGHTEN 1, which weakens the development case and commercialization path.
Physicians may not adopt the office-based procedure and payers may not provide adequate coverage.
The May 2024 reduction in force reduced experienced scientific and manufacturing staff, increasing execution risk.
Approved and pipeline CRS therapies may offer better convenience, efficacy, or lower cost.
TYRA · Pharmaceutical Preparations
LRMR · Pharmaceutical Preparations
GYRE · Pharmaceutical Preparations
Gyre Therapeutics is a commercial-stage biopharmaceutical company focused on small-molecule therapies for organ fibrosis and inflammatory diseases.
OTLK · Biological Products, (No Diagnostic Substances)
LSTA · Pharmaceutical Preparations
Lisata Therapeutics is a clinical-stage pharmaceutical company focused on developing certepetide, an investigational therapy designed to improve delivery of anti-cancer drugs into solid tumors.
LYEL · Pharmaceutical Preparations
Lyell Immunopharma is a U.S.-based late-stage clinical cell therapy company developing next-generation autologous CAR T-cell therapies for cancer.
: 28/04/2026